top of page
  • Writer's pictureFutureMeds

FutureMeds appoints Dr Radoslaw Janiak as CEO.

Updated: Jan 24, 2023

FutureMeds, a UK based Dedicated Research Sites Network announces the appointment of Dr Radoslaw Janiak as its Chief Executive Officer.

With its operations in UK, Poland and Ukraine, FutureMeds has aggressive expansion plans to build Dedicated Research Sites in key geographical locations across Europe.

Dr Janiak graduated from Medical University, Warsaw and began his career as a medical doctor at Praski Hospital, Warsaw. He opened one of the first Dedicated Research Sites in Poland which was subsequently acquired by Synexus - one of their first steps in expanding outside the UK. On joining Synexus, Dr Janiak became responsible for operations in Poland, Ukraine, Hungary, Bulgaria and Romania, before being appointed as COO. After acquisition by PPD, Dr Janiak took on the position of President and Chief Operating Officer, leading Synexus in Europe, USA, Africa and Asia.

Dr Janiak commented on his appointment: “I am extremely happy to be joining FutureMeds and lead the expansion of this exciting new organisation. I have full confidence that in this current challenging period, when speed is of the essence, independent Site Networks like FutureMeds will contribute significantly to Medical Research. Our current Sites in Poland are ready now with a flexible model to execute trials with Telemedicine Solutions. And we continue to plan and execute the expansion of our footprint in Europe.”

About FutureMeds

FutureMeds is a fast-growing independent Dedicated Research Site Network supporting pharmaceutical companies, Sponsors and CROs and contributing to research to find effective treatments and medications for all patients who need them.

FutureMeds’ Dedicated Research Site teams strive to accelerate study timelines, streamline processes, lower costs and improve data quality to help accelerate patient access to new treatments.

Through acquisitions and a strategic focus on patient experience, FutureMeds has developed qualified patient pools across Europe that enables faster patient enrollment and strong retention and help generate more accurate results.

Follow us on LinkedIn

Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.


Opmerkingen zijn uitgezet.
bottom of page